S4: E4: Life story of Dr. Michael Abramoff. Eye Tea - Ophthalmology podcast - Deep dive series, Part 1

In this 1st part of the 3 part deep dive with Dr. Michael Abramoff, Dr. Gagan Kalra (host) delves into the life story of Dr. Abramoff. Referenced reading materials: ~reimbursement of medical AI (Open Access -Free) Dr. Michael Abramoff, MD, PhD, (FARVO) is the Robert C. Watzke, MD Professor of Ophthalmology and Visual Sciences at the University of Iowa, with a joint appointment in the College of Engineering, a fellowship-trained retina specialist, computer scientist, and entrepreneur. He is an IEEE Fellow, and an ARVO Gold Fellow.  In 1989-1990, he did a postdoc at the RIKEN neural networks research lab in Japan. As an expert in machine learning and image analysis, Dr. Abramoff was one of the original developers of a widely-used open-source image analysis app, ImageJ. His research has been continuously funded since 2004 by National Eye Institute, the Veterans Administration, the Beckman Foundation and other federal, state and philanthropic funding agencies in the U.S. and Europe. Dr. Abramoff is the Founder and Executive Chairman of Digital Diagnostics, the Autonomous AI diagnostics company that was the first in any field of medicine to get FDA clearance for an autonomous AI. In primary care, the AI system can instantaneously diagnose diabetic retinopathy and diabetic macular edema at the point of care. This device, IDX-DR, is now part of ADA’s Standard Diabetes Care and Dr. Abramoff has also developed an ethical foundation for autonomous AI that was used during the design, validation, and regulatory and payment pathways for autonomous AI.  As the author of over 300 peer-reviewed publications in this field, he has been cited over 35,000 times, and is the inventor on 17 issued patents and many patent applications. Dr. Abramoff has mentored dozens of engineering graduate students, ophthalmology residents, and retina fellows. His passion is to use AI to improve the affordability, accessibility and quality of care.

There are no comments yet.

Please log in to write the first comment.